x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012929
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asn101 of human TRPV3. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | TRPV3 |
| UniProt No. | Q8NET8 |
| Gene ID | 162514 |
| Gene Description | The transient receptor potential cation channel subfamily V member 3 is a widely expressed ligand-gated ion channel protein that acts in temperature detection between 22º C and 40º C. Related transient receptor proteins respond to different temperature ranges; TRPA1 responds to cold temperatures and TRPM1 to cool, while warmer temperatures elicit response from TRPV3 and TRPV4. Noxious heat or painful temperatures correlate with TRPM8 and TRPV1 activity. TRPV3 is found in association with TRPV1 and is thought to modulate activity of this noxious heat-responsive protein. Increased TRPV1 and TRPV3 protein expression is correlated with nervous injury, while reduced expression of both may be see in cases of diabetic skin neuropathy. Recent evidence implicates TRPV3 in pruritic dermatitis, or itching associated with eczema and related skin disorders. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
